Business Description
ME Therapeutics Holding Inc
NAICS : 541714
SIC : 3741
Compare
Compare
Traded in other countries / regions
METX.CanadaQ9T.GermanyMETXF.USA IPO Date
2024-02-27Description
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 41.35 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 35.55 | |||||
| Quick Ratio | 35.55 | |||||
| Cash Ratio | 35.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -443.85 | |||||
| ROA % | -407.66 | |||||
| ROIC % | -3787.76 | |||||
| ROC (Joel Greenblatt) % | -29103.7 | |||||
| ROCE % | -443.75 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 60.94 | |||||
| Price-to-Tangible-Book | 58.95 | |||||
| EV-to-EBIT | -24.92 | |||||
| EV-to-EBITDA | -24.92 | |||||
| EV-to-FCF | -161.01 | |||||
| Price-to-Net-Current-Asset-Value | 58.95 | |||||
| Price-to-Net-Cash | 58.95 | |||||
| Earnings Yield (Greenblatt) % | -4.01 | |||||
| FCF Yield % | -0.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:METXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ME Therapeutics Holding Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.122 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0 | ||
| 20-Day SMA ($) | 2.9474 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 2.9474 - 2.9474 | ||
| Shares Outstanding (Mil) | 25.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ME Therapeutics Holding Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ME Therapeutics Holding Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ME Therapeutics Holding Inc Frequently Asked Questions
What is ME Therapeutics Holding Inc(METXF)'s stock price today?
The current price of METXF is $2.95. The 52 week high of METXF is $2.95 and 52 week low is $2.95.
When is next earnings date of ME Therapeutics Holding Inc(METXF)?
The next earnings date of ME Therapeutics Holding Inc(METXF) is .
Does ME Therapeutics Holding Inc(METXF) pay dividends? If so, how much?
ME Therapeutics Holding Inc(METXF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers